Anti-CD20 mAbs in development
| Name . | Company . | Type (all IgG1κ) . | Status . |
|---|---|---|---|
| Rituximab | Roche/Genentech | Chimeric | Approved |
| Ofatumumab | Novartis | Fully human | Approved |
| Obinutuzumab | Roche/Genentech | Humanized, glycoengineered | Approved |
| Ublituximab | TG Therapeutics | Chimeric, glycoengineered | Phase 3 |
| Veltuzumab | Immunomedics | Humanized | Phase 2 |
| Ocaratuzumab | Mentrik Biotech | Humanized, Fc mutant | Apparently stopped |
| Ocrelizumab | Roche/Genentech | Humanized | Stopped in hematology |
| PRO131921 | Roche/Genentech | Humanized, Fc mutant | Stopped |
| Name . | Company . | Type (all IgG1κ) . | Status . |
|---|---|---|---|
| Rituximab | Roche/Genentech | Chimeric | Approved |
| Ofatumumab | Novartis | Fully human | Approved |
| Obinutuzumab | Roche/Genentech | Humanized, glycoengineered | Approved |
| Ublituximab | TG Therapeutics | Chimeric, glycoengineered | Phase 3 |
| Veltuzumab | Immunomedics | Humanized | Phase 2 |
| Ocaratuzumab | Mentrik Biotech | Humanized, Fc mutant | Apparently stopped |
| Ocrelizumab | Roche/Genentech | Humanized | Stopped in hematology |
| PRO131921 | Roche/Genentech | Humanized, Fc mutant | Stopped |